MPM Capital
MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed MPM Capital Information
Geographic Data
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
966,501Website Global Rank
28,580Website Monthly Traffic
Twitter Followers
Description
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 1/2008 | Peptimmune | Series D | 8.2M |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 4/2004 | Affymax | Series C | 20M |
| 5/2003 | Cellerant Therapeutics | Series A | 10M |
| 7/2007 | Xanodyne | Series A | 25M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2014 | Cerecor | Series B | 32M |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 6/2003 | CryoCor | Series C | 27.5M |
| 10/1999 | Pharmasset | Series B | 3.9M |
| 11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
| 9/2008 | Valeritas | Series A | 50M |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 10/2015 | 23andMe | Series E | 115M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 9/2000 | CryoCor | Series A | 7M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 1/2011 | 23andMe | Series C | 9M |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2004 | Arriva Pharmaceuticals | Series D | - |
| 5/2005 | Oxagen | Series B | 0 |
| 11/2004 | Neosil | Series A | 32M |
| 1/2013 | Aratana Therapeutics | Series C | 0 |
| 1/2017 | Maverick Therapeutics | Venture Round | 125M |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 8/2004 | Ceregene | Series B | 32M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 2/2006 | ARYx Therapeutics | Series E | 30.4M |
| 7/2005 | Xanodyne | Series A | 170M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 7/2012 | Chiasma | Series D | 38.5M |
| 10/2013 | Mitobridge | Series A | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 4/2016 | Harpoon Therapeutics | Series A | 15M |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
| 5/2012 | NeoVista | Venture Round | 6M |
| 11/2011 | Meritage Pharma | Venture Round | 6.5M |
| 5/2008 | SAI Life Sciences | Private Equity Round | 20M |
| 7/2009 | iPierian | Venture Round | 11.5M |
| 8/2008 | Peplin | Private Equity Round | 24M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 1/2020 | BioIntervene | Series A | 30M |
| 2/2008 | Epizyme | Series A | - |
| 7/2008 | Peptimmune | Series D | 8.9M |
| 3/2020 | ElevateBio | Series B | 170M |
| 4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 11/2020 | Umoja Biopharma | Series A | 53M |
| 2/2015 | Chiasma | Series E | 70M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 7/2005 | Affymax | Series D | 60M |
| 11/2006 | Chiasma | Series C | 44M |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 9/2011 | Valeritas | Series C | 150M |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 1/2002 | BioXell | Series A | 19.7M |
| 5/2005 | Cellerant Therapeutics | Series B | 16M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 12/2016 | TCR2 | Series A | 44.5M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 3/2010 | Motus Therapeutics | Series A | 21M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 1/2020 | Orna Therapeutics | Seed Round | 20M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 9/2007 | JapanBridge | Series A | 6.5M |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 1/2011 | Aratana Therapeutics | Series A | 0 |
| 3/2015 | Clinical Ink | Venture Round | 20M |
| 3/2008 | EKR Therapeutics | Series D | 50M |
| 10/2003 | Cotherix | Series C | 55M |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 12/2002 | Intracel Holdings Corporation | Series B | 16M |
| 4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 6/2006 | VLST Corporation | Series B | 55M |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 12/2012 | 23andMe | Series D | 50M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 3/2009 | Surface Logix | Series E | 15M |
| 3/2008 | TriVascular | Series A | 65M |
| 7/2016 | Oncorus | Series A | 57M |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 3/2001 | Pharmasset | Series C | 7.4M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 8/2010 | EndoGastric Solutions | Series F | 0 |
| 6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 6/2020 | Cullinan Oncology | Series B | 98.5M |
| 10/2017 | Cullinan Oncology | Series A | 150M |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 8/2003 | Archus Orthopedics | Series B | 18M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 4/2007 | Cellerant Therapeutics | Series B | 0 |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 4/2018 | Tetherex | Series B | 50M |
| 1/2010 | Alnara Pharmaceuticals | Series B | 35M |
| 11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
| 8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 10/2009 | Epizyme | Series B | 32M |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 7/2005 | Peptimmune | Series C | 20.4M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 3/2009 | NeoVista | Series D | 18M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 9/2004 | EndoGastric Solutions | Series B | 12M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
| 12/2011 | Aratana Therapeutics | Series B | 15M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2008 | Humanigen | Series D | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 7/2011 | Nevro | Series B | 58M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 11/2008 | Radius Health | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 9/1999 | Pointshare | Series C | 40M |
| 11/2000 | Epigenomics | Venture Round | 24.1M |
| 7/2003 | Tercica | Series B | 44M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 10/2007 | Allozyne | Series B | 30M |
| 7/2013 | InformedDNA | Seed Round | 3M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2016 | Potenza Therapeutics | Venture Round | 30M |
| 9/2008 | ForteBio | Series C | 25M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2005 | Hypnion | Series B | 0 |
| 7/2014 | Valeritas | Series D | 45M |
| 4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
| 11/2019 | SiO2 Materials Science | Venture Round | - |
| 8/2004 | Pharmasset | Series D | 40M |
| 9/2022 | Photys | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | ElevateBio | Series D | 0 |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 6/2003 | Xoft | Series B | 0 |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 4/2003 | Epigenomics | Series C | 22.5M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 3/2005 | Humanigen | Series B | 20M |
| 6/2003 | EndoGastric Solutions | Series A | 5M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 1/2009 | TaiGen Biotechnology | Series C | 0 |
| 3/2004 | TaiGen Biotechnology | Series B | 0 |
| 7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
| 6/2007 | Ceregene | Series C | 0 |
| 7/2011 | Radius Health | Series C | 66M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 7/2003 | Intercell | Series C | 50M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 10/2004 | BioXell | Series C | 29M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 3/2003 | Peptimmune | Series B | 41.2M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 6/2006 | Peptimmune | Series C | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 8/2010 | TriVascular | Series C | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 3/2013 | Nevro | Series C | 0 |
| 11/2009 | Oxagen | Series C | 0 |
| 5/2009 | Proteon Therapeutics | Series B | 50M |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 5/2010 | Ntprx | Series B | 43M |
| 1/2005 | CHF Solutions | Venture Round | 22.9M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 11/2010 | iPierian | Series B | 29M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 1/2010 | Dragonfly Sciences | Venture Round | - |
| 12/2006 | NeoVista | Series C | 41M |
| 1/2002 | CryoCor | Series B | 12M |
| 3/2019 | TriNetX | Series D | 40M |
| 5/2015 | Blade Therapeutics | Seed Round | - |
| 6/2002 | Cardiac Dimensions | Series B | 12M |
| 6/2013 | Pierian Biosciences | Private Equity Round | 18M |
| 11/2009 | EndoGastric Solutions | Series E | 0 |
| 10/2009 | EndoGastric Solutions | Venture Round | 0 |
| 2/2003 | Synergia Pharma | Series A | 2M |
| 11/2006 | Solasia Pharma | Pre Seed Round | - |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 8/2011 | Proteon Therapeutics | Series C | 15.2M |
| 6/2007 | Athersys | Venture Round | 0 |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2011 | Mitobridge | Seed Round | - |
| 3/2004 | Restore Medical | Series C | 26.5M |
| 1/2002 | Archus Orthopedics | Series A | - |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 12/2008 | Humanigen | Series D | 12M |
| 10/2004 | PharmAthene | Series B | 50M |
| 1/2012 | CoStim Pharmaceuticals | Seed Round | - |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 9/2022 | Photys Therapeutics | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
